Following continued campaigning and concerted parliamentary pressure, the government has announced that it has included Sodium Valproate among a review of three major medical issues; the other two being vaginal mesh implants and the pregnancy test, Primodos.
Since the 1970s, Sodium Valproate (Epilim) has been used as a treatment for epilepsy, bipolar disorder and migraine. However, babies developing in the womb who have been exposed to Sodium Valproate have a 40% risk of developing autism, low IQ and learning disabilities, with a 10% chance of developing physical abnormalities.
Leading Sodium Valproate solicitor, David Gazzard, who has been in close contact with the All-Party Parliamentary Group (APPG) on Sodium Valproate and Other Anti-Epileptic Drugs in Pregnancy, has been invited to contribute to submissions to the review.
David said “I feel privileged to have been asked to contribute to the APPG’s evidence submission. It is high time that the families affected by sodium valproate receive the financial care and support package presently under consideration.”